Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally
Summary:
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally1
Since the start of the donation program in 2005, Novartis has donated approximately 4 million tablets of Egaten, valued at USD 41 million, helping to treat around 2 million fascioliasis patients worldwide
Egaten is currently the only treatment for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines
Article
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally1
Since the start of the donation program in 2005, Novartis has donated approximately 4 million tablets of Egaten, valued at USD 41 million, helping to treat around 2 million fascioliasis patients worldwide
Egaten is currently the only treatment for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines
Agreement expected to reduce Novartis greenhouse gas emissions by more than 220,000 metric tons per year, equivalent to removing more than 48,000 passenger vehicles from the road each year
Summary:
Virtual Power Purchase Agreement (VPPA) with renewable energy company, Invenergy, adds 100 megawatts of clean power to the electrical grid.
VPPA expected to be online in 2019 and to reduce Novartis greenhouse gas emissions by more than 220,000 metric tons per year, equivalent to removing more than 48,000 passenger vehicles from the road each year
Electricity will be generated from Invenergy’s Santa Rita East wind farm near San Angelo, Texas
Project in line with Novartis’ sustainability goals to substantially reduce carbon footprint and increase use of renewable energies
Press Release
Virtual Power Purchase Agreement (VPPA) with renewable energy company, Invenergy, adds 100 megawatts of clean power to the electrical grid.
VPPA expected to be online in 2019 and to reduce Novartis greenhouse gas emissions by more than 220,000 metric tons per year, equivalent to removing more than 48,000 passenger vehicles from the road each year
Electricity will be generated from Invenergy’s Santa Rita East wind farm near San Angelo, Texas
Project in line with Novartis’ sustainability goals to substantially reduce carbon footprint and increase use of renewable energies
Alcon Cares to donate 100 reprocessed Infiniti® units to clinics in underserved areas with the goal of performing 200,000 phaco cataract surgeries and training 400 doctors by the end of December 2020.
Article
Alcon, the global leader in eye care and a division of Novartis, today announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to perform phacoemulsification (or “phaco”), a key step in the cataract surgery procedure. Alcon Cares, a foundation that oversees equipment and product donations to those in need, will give 100 reprocessed Infiniti units to eligible clinics in Asia, Central and South America, and Africa over the next three years, making it one of the largest eye care equipment donations of its kind.
Today, the Novartis Foundation announces the creation of a network of global and local implementation partners who will work together to co-design interventions to address São Paulo’s urban priorities and improve cardiovascular health.
Article
Less than three months after the selection of São Paulo, Brazil as the third city of the urban health initiative Better Hearts Better Cities, the Novartis Foundation announced the creation of a network of global and local implementation partners.
Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years
Commitment includes expanding access to pediatric antimalarials and implementing capacity-building programs to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90% by 2030
New opinion research in Africa shows 2030 malaria elimination targets are at risk; leaders urge investment in innovative malaria prevention and treatment tools
Press Release
Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years
Commitment includes expanding access to pediatric antimalarials and implementing capacity-building programs to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90% by 2030
New opinion research in Africa shows 2030 malaria elimination targets are at risk; leaders urge investment in innovative malaria prevention and treatment tools
Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis
Cryptosporidiosis is the second leading cause of infectious diarrhea in children
Private companies, governments, non-governmental organizations, academia, and other stakeholders need to work together to create sustainable solutions for global health issues.
Press Release
Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis
Cryptosporidiosis is the second leading cause of infectious diarrhea in children
Private companies, governments, non-governmental organizations, academia, and other stakeholders need to work together to create sustainable solutions for global health issues.
The Global Partnership for Zero Leprosy brings together organizations including the Novartis Foundation, ILEP, IDEA, the Task Force for Global Health and national leprosy programs, with support from the World Health Organization (WHO).
Article
Innovation in science offers new opportunities and hope for achieving zero leprosy.
The Global Partnership for Zero Leprosy will coordinate research in new diagnostics, strategies to interrupt transmission, translation of new evidence into action, and will help strengthen national programs.
World Leprosy Day (Jan 28) raises awareness of a disease with more than 200,000 new diagnoses per year, primarily in India, Brazil and Indonesia.
For the fifth consecutive year, Novartis is publishing an annual Corporate Responsibility (CR) Report. The report is divided into four chapters based on our CR material clusters: access to healthcare, innovation, patient health and safety and ethical business practices. Each chapter provides readers with focused information on our approach and performance in each of these areas.
The report has been prepared in accordance with the GRI Standards: Core option. And it supplements the CR chapter in the Novartis 2017 Annual Report.
DAVOS, Switzerland, January 23, 2018 /3BL Media/ -- Today at the World Economic Forum (WEF) in Davos, over 30 leading companies across 16 sectors joined forces to implement the circular economy through WBCSD’s newest initiative, Factor10. Collectively responsible for USD $1.3 trillion in annual revenues, the companies in Factor10 represent a powerful business effort scale up momentum for circular economy solutions.
The Ghana telemedicine program, with the support of the Novartis Foundation, is now being scaled across the nation by Ghana Health Service.
Novartis Foundation and Ghana Health Service highlight the successful integration of the program in national health services as a model for multisector working.
National coverage of telemedicine services is expected to be possible by 2019.
Digital health learnings from the program can be used to expand quality healthcare in other areas.
Article
The Ghana telemedicine program, with the support of the Novartis Foundation, is now being scaled across the nation by Ghana Health Service.
Novartis Foundation and Ghana Health Service highlight the successful integration of the program in national health services as a model for multisector working.
National coverage of telemedicine services is expected to be possible by 2019.
Digital health learnings from the program can be used to expand quality healthcare in other areas.
